Ovarian sex cord-stromal tumors are a group of rare neoplasms, considered to be low-grade malignant tumors. The Sertoli-Leydig cell tumors subgroup occur mostly in young patients and reveals itself with virilization symptoms. Here we report a rare case of a voluminous well differentiated tumor in a 75-year-old patient with no sign of secretory effects. The radical treatment was impossible, and a palliative chemotherapy was indicated.

Background: Epidermal growth factor receptor (EGFR) mutations are potential therapeutic targets leading to improved response and progression free survival with EGFR tyrosine kinase inhibitors in NSCLC. Some studies have demonstrated a genetic divergence of EGFR mutation rates according to ethnicity with highest frequencies reported in Asian populations (47%). In this study, we conducted a systematic review of publications related to the frequency of the EGFR mutation in Middle East and African regions to compare the results with those of asian populations. Methods: We used PubMed and the Cochrane Library databases to conduct a literature search using the terms "[EGFR] AND [mutation] AND [Non Small Cell Lung Cancer] AND [Middle East OR Africa]." We assessed studies published in English and French from 2004 until 2016. Results: Ten relevant studies were included in this systematic review. Overall, 1215 patients with non-small cell lung cancer (NSCLC) were included in this analysis. The overall ratio of male to female patients was 2.15. Of total patients included, 41.1% had never smoked and 85.8% had been diagnosed with adenocarcinoma. In 8 of the 10 studies, polymerase chain reaction (PCR) analyses were conducted to identify EGFR mutations. In total, 257 patients had an EGFR mutation, corresponding to a prevalence of 21.2%. The most frequent abnormality detected in all of the studies was in exon 19. In addition, all studies concluded the presence of a correlation between EGFR mutation status and female sex, non-smoking status, and adenocarcinoma subtype. Conclusions: The EGFR mutation frequency in Middle East and African patients is higher than that shown in white populations but still lower than the frequency reported in Asian NSCLC populations.Legal entity responsible for the study: Zineb Benbrahim. Funding: Has not received any funding.

No abstract

Renal cell carcinoma (RCC) is a common cancer, but its pancreatic metastasis is unusual. We report a case of a 50-year-old male who was under the first line of treatment for a metastatic RCC since 2009. In August 2015, he showed up to the day unit with a cholestatic jaundice, and the investigations led to the discovery of a liver function alteration and a pancreatic mass. The biopsy of the inoperable mass revealed a RCC metastasis. The localization of this metastasis complicated the management of the disease due to haemorrhage and anemia. An embolization was performed to control the local complications. The patient was commenced on everolimus but with modest results forcing us to start exclusive palliative care.

A 51-year-old female with a history of radical mastectomy with axillary lymph node dissection, adjuvant chemotherapy and radiation for a breast cancer was referred to the emergency room due to cholangitis. A CT scan showed a common bile duct mass invading the duodenum. After bile draining, the investigations led to an undifferentiated carcinoma with positive hormonal receptors. The diagnosis of a breast cancer recurrence was established and the patient was commenced on taxane therapy.